URGN urogen.com: קפיטליזציה חשבונאית

The development of UroGen Pharma Ltd. (URGN) relies on the commercial success of Jelmyto and the status of UGN-102. This chart reflects a current market value of -0.13, which correlates with the burn rate and insurance coverage. The proprietary gel delivery system in uro-oncology creates significant barriers to entry for competitors. Meanwhile, the business's environmental footprint is minimal, limited only to the proper disposal of laboratory waste.

The development of RTGel targeted hydrogels and the success of Jelmyto are building the material foundation of UroGen Pharma Ltd. (URGN). These business drivers directly impact the difference between the company's total assets and liabilities. This metric measures the actual value of net assets, reflecting the issuer's internal financial stability. It is critical for investors to compare this objective value with market expectations. The trend in the firm's book value demonstrates the business's actual margin of safety.